 Edesa Biotech Inc NASDAQ: EDSA is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5 reduction in the risk of dying when treated with EB05 over standard of care. 